Company intelligence / Profile preview
R-Tech Ueno
Tokyo, Japanprnewswire.com ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
A Japanese biopharmaceutical company specializing in ophthalmology and dermatology therapeutics. Developed Rescula® (unoprostone) for glaucoma and manufactured AMITIZA® (lubiprostone). Acquired by Sucampo Pharmaceuticals in December2015 for $275M[5][6]. Maintained active pipeline including VAP-1 inhibitors and recombinant albumin formulations[3][8].
- Therapeutic areas
- OphthalmologyMen's HealthDermatology
- Modalities
- Small molecules(Recombinant) proteins
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Request access →03
Partnerships
Novozymes Biopharma DK A/SChemo-Sero-Therapeutic Research Institute(Kaketsuken)Mylan/Takeda/Harbin Gloria
Beyond the preview
Go deeper on R-Tech Ueno.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on R-Tech Ueno.